Navigation Links
Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services
Date:8/1/2013

Boulder, CO (PRWEB) August 01, 2013

Flagship Biosciences, a leading provider of tissue analysis for pharmaceutical and medical device development, has added biostatistics services for preclinical and clinical trials support.

A complete service in tissue analysis requires cancer biologists, pathologists, image analysis experts and biostatisticians all working together. With the addition of biostatistics, Flagship expands its world-class team to fully address a given tissue study, whether early stage biomarker development or clinical trial patient segmentation, or the development of an immunohistochemistry companion diagnostic. Given the changes and fragmentation of outsourcing in the industry today, a team with this set of experts can be a huge value in both time and quality to any drug or device development endeavor, whether a virtual company or a large established pharmaceutical firm.

The pharmaceutical industry and the discipline of pathology are both independently transforming. Large pharmaceutical firms previously relied on in-house pathology and statistical support, and a pathologist and statistician would work together regularly. With downsizing at large pharmaceutical companies and the growth of smaller biotechs and new virtual business models, these two disciplines are frequently now out-sourced. Even with retention of in-house capabilities, the researchers often find they have only limited accessibility to the statisticians, and the iterative process of data interpretation becomes difficult. The essential communication between what the results are by a pathologist and what the results mean by a statistician are frequently disrupted, leading to incomplete analysis of the data.

The discipline of pathology is also undergoing a decade long transition to a digital discipline where quantitation will be expected. “Where previously we relied on a pathologist to give a manual subjective score, there were limits to what a statistician could do with the data, said Dr. Steven Potts, CEO of Flagship Biosciences. “With the newer techniques that Flagship Biosciences is developing, there is a greater need for biostatistics, and also an emerging discipline of pathology statistics. This growth is a natural expansion as the discipline of tissue-based pathology develops towards a more quantitative discipline. Our expansion of in-house biostatistics capabilities will also strengthen our ongoing tissue-based companion diagnostics programs.”

With new approaches to multiple measures of tissue markers which are rich in quantitative data, multivariate statistics becomes central. Even with single-value measurements in immunohistochemistry or immunofluorescence, the correct approach to determining a therapeutic cut-point requires statistics expertise. A statistician must fully understand the process of a pathology study in order to provide advice on critical decisions like sample size, adequate power, outlier analysis, and bias.

Flagship Biosciences is a fast-growing histopathology services firm that works with over one hundred drug and medical device clients and fourteen of the largest fifteen global pharmaceutical companies. Flagship supports discovery and CLIA/GCP clinical trials in quantitative pathology. Flagship’s biostatistics services improve upon their industry-leading digital pathology knowledge and expertise.

Read the full story at http://www.prweb.com/releases/2013/8/prweb10981722.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
2. BioXcel Launches Its Flagship Product, PharmGPS™
3. Clinovo, Leading CRO in the Bay Area, Endorsed by Medical Device Company for Their Flagship System: Clincapture
4. Neurocrine Biosciences Reports Second Quarter 2013 Results
5. Centrillion Biosciences Announces Winners of Next-gen Sequencing Innovation Grant Program
6. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
7. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
8. Eagle Biosciences Introduces Highly Sensitive Calprotectin ELISA Assay Kit
9. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
10. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
11. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 AquaBounty Technologies, Inc. (AIM: ... productivity in aquaculture and a majority-owned subsidiary of Intrexon ... has completed the listing of its common shares on ... from Intrexon. "AquaBounty,s listing on NASDAQ represents ... our exposure to the U.S. markets as we advance ...
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , ... from around the world, was today awarded the "Best Science & Technology Social ... on merit and decided upon by a dedicated team of researchers and analysts. ...
(Date:1/19/2017)... ... 19, 2017 , ... DaVita Clinical Research (DCR), ... and device development, and Prism Clinical Research , a leader in providing ... Verified Clinical Trials (VCT) has been selected by both companies as an ...
(Date:1/19/2017)... 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW ... therapies for operable and inoperable solid tumor cancers, announced ... Officer of NW Bio, will present at the Phacilitate ... the Hyatt Regency Hotel in Miami, Florida ... session entitled "New Therapeutic Approaches – Expanding the Reach ...
Breaking Biology Technology:
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
Breaking Biology News(10 mins):